124 related articles for article (PubMed ID: 21828377)
1. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.
Galsky MD; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Ann Oncol; 2012 Apr; 23(4):1037-44. PubMed ID: 21828377
[TBL] [Abstract][Full Text] [Related]
2. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors.
Akshintala S; Marcus L; Warren KE; Murphy RF; Sissung TM; Srivastava A; Goodspeed WJ; Goodwin A; Brewer CC; Zalewski C; King KA; Kim A; Figg WD; Widemann BC
Pediatr Blood Cancer; 2015 Apr; 62(4):603-10. PubMed ID: 25556988
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.
Gietema JA; de Vries EG; Sleijfer DT; Willemse PH; Guchelaar HJ; Uges DR; Aulenbacher P; Voegeli R; Mulder NH
Br J Cancer; 1993 Feb; 67(2):396-401. PubMed ID: 8431374
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
[TBL] [Abstract][Full Text] [Related]
6. A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function.
Azaro A; Rodón J; Machiels JP; Rottey S; Damian S; Baird R; Garcia-Corbacho J; Mathijssen RHJ; Clot PF; Wack C; Shen L; de Jonge MJA
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1185-1197. PubMed ID: 27796539
[TBL] [Abstract][Full Text] [Related]
7. Satraplatin: an orally available platinum analog for the treatment of cancer.
Choy H
Expert Rev Anticancer Ther; 2006 Jul; 6(7):973-82. PubMed ID: 16831070
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.
Takimoto CH; Graham MA; Lockwood G; Ng CM; Goetz A; Greenslade D; Remick SC; Sharma S; Mani S; Ramanathan RK; Synold TW; Doroshow JH; Hamilton A; Mulkerin DL; Ivy P; Egorin MJ; Grem JL
Clin Cancer Res; 2007 Aug; 13(16):4832-9. PubMed ID: 17699862
[TBL] [Abstract][Full Text] [Related]
9. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.
Takimoto CH; Remick SC; Sharma S; Mani S; Ramanathan RK; Doroshow JH; Hamilton A; Mulkerin D; Graham M; Lockwood GF; Ivy P; Egorin M; Greenslade D; Goetz A; Grem JL
Semin Oncol; 2003 Aug; 30(4 Suppl 15):20-5. PubMed ID: 14523791
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of the oral platinum agent satraplatin in combination with oral vinorelbine in patients with advanced solid malignancies.
Gallerani E; Cathomas R; Sessa C; Digena T; Bartosek AA; Dal Zotto L; von Moos R
Onkologie; 2013; 36(1-2):40-5. PubMed ID: 23429330
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment.
Kelly KR; Gabrail N; Weitman S; Sarantopoulos J; Olszanski AJ; Edenfield W; Venitz J; Reddy G; Yang A; Hasal SJ; Lockhart AC
Cancer Chemother Pharmacol; 2016 Nov; 78(5):929-939. PubMed ID: 27638045
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function.
Massari C; Brienza S; Rotarski M; Gastiaburu J; Misset JL; Cupissol D; Alafaci E; Dutertre-Catella H; Bastian G
Cancer Chemother Pharmacol; 2000; 45(2):157-64. PubMed ID: 10663631
[TBL] [Abstract][Full Text] [Related]
13. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
Sharma S; Witteveen PO; Lolkema MP; Hess D; Gelderblom H; Hussain SA; Porro MG; Waldron E; Valera SZ; Mu S
Cancer Chemother Pharmacol; 2015 Jan; 75(1):87-95. PubMed ID: 25377157
[TBL] [Abstract][Full Text] [Related]
14. An update on satraplatin: the first orally available platinum anticancer drug.
Kelland LR
Expert Opin Investig Drugs; 2000 Jun; 9(6):1373-82. PubMed ID: 11060749
[TBL] [Abstract][Full Text] [Related]
15. The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.
Marcus L; Murphy R; Fox E; McCully C; Cruz R; Warren KE; Meyer T; McNiff E; Balis FM; Widemann BC
Cancer Chemother Pharmacol; 2012 Jan; 69(1):247-52. PubMed ID: 21706317
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.
Tan AR; Sarantopoulos J; Lee L; Reyderman L; He Y; Olivo M; Goel S
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1051-61. PubMed ID: 26433580
[TBL] [Abstract][Full Text] [Related]
19. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Takimoto CH; Remick SC; Sharma S; Mani S; Ramanathan RK; Doroshow J; Hamilton A; Mulkerin D; Graham M; Lockwood GF; Ivy P; Egorin M; Schuler B; Greenslade D; Goetz A; Knight R; Thomas R; Monahan BP; Dahut W; Grem JL;
J Clin Oncol; 2003 Jul; 21(14):2664-72. PubMed ID: 12860942
[TBL] [Abstract][Full Text] [Related]
20. Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation.
McKeage MJ
Drugs; 2007; 67(6):859-69. PubMed ID: 17428104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
